RECENT COMMENTS

Kathy Redmond: Readers may have noticed that ESO has deleted a number of comments on this article. This is because [...]   »Read more

Pongsri (Sex and cancer): I teach body image and sexuality in cancer survivors for specialty 4 month cancer nurse program. Thi [...]   »Read more

DR Jennifer L Scott (Sex and cancer): Togehter with my colleague Prof Karen Kayser I have published a review of RCT of interventions to en [...]   »Read more

Dr O. Abimbola Oluwatosin (Sex and cancer): I teach sexuality in Nursing at post graduate level. This article is very useful and will be added t [...]   »Read more

Dr. Yannis Vassiliou (political oncology): A great article, well done! I was deeply disappointed by the comments of the Turkish colleagues, wh [...]   »Read more

 

Article type: Patient Voice

Keywords: disability rights laws, cancer patients, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Just the job? It’s time to try out the new disability rights laws

By now, all EU Member States should have outlawed discrimination at work on the grounds of disability. Will this be enough to protect cancer patients from being forced out of their jobs, and give them the right to continue working at the level they want? If not, now is the time to contact the Commission and complain.

» Anna Wagstaff

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.